Exploring Potential: Emerging Thresholds and Catalysts for the Future (HCWB, XRTX, VYNE, NRSN, CNTX)
In this week's list of five penny stocks, we aim to identify resistance breakthroughs and anticipate catalysts. Stay proactive in spotting potential upward shifts and precise entry points. Avoid chasing bottoms; exercise patience and await confirmation through a breakout.
HCW Biologics Inc. (NASDAQ: HCWB) - Last week, the company closed up 2% at 1.23. In November, they released positive business highlights, confirming consistent results in humans matching preclinical animal studies for HCW9218. The company aims to finish the initial phase of ongoing cancer studies in late 2023 or early 2024 and plans to submit an IND application for an autoimmune disorder trial by the end of 2023. We'll be closely monitoring both company updates and the potential breakout above the $1.33 resistance level.
XORTX Therapeutics Inc. (NASDAQ: XRTX) - Last week, the company closed up 14% at $2.31. In August, they submitted an Orphan Drug Designation application for XORLO™ to the EMA, specifically for treating autosomal dominant polycystic kidney disease (ADPKD). The EMA's COMP office is set to review the application with a decision expected in December of 2023. We'll be monitoring company updates and watching for a potential resistance break at $2.49 for further upward momentum.
VYNE Therapeutics Inc. (NASDAQ: VYNE) - Last week, the company closed down 6% at $2.33. In November of 2023, the CEO highlighted substantial progress, especially with positive Phase 1b trial results for VYN201 in vitiligo treatment. They're on schedule to submit the VYN202 IND by year-end 2023, initiating a Phase 1a trial in Q1 2024. If successful, Phase 1b trials for plaque psoriasis and adult-onset rheumatoid arthritis are planned for H2 2024. We'll be monitoring for a potential breakout above the $2.48 resistance level and anticipating future updates.
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) - Last week, the company closed slightly under 1% higher at $0.78. In December of 2023, the company shared additional positive efficacy data from its Phase 2b trial (PARADIGM) of PrimeC for ALS. Primary biomarker results are anticipated in H1 2024. Discussions with regulatory agencies regarding PrimeC's effects and safety are planned for the End of Phase 2 meeting in H1 2024. Additionally, Neurofilament biomarker results from a collaboration with Biogen are expected in January 2024. We'll be watching for future updates and a potential resistance breakout in the $0.86-$0.87 range.
Context Therapeutics Inc. (NASDAQ: CNTX) - Closing last week's trading session down approximately 1% at $1.13. In November, the company highlighted progress on CTIM-76, a Claudin 6 x CD3 bispecific antibody, moving towards its first-in-human clinical study. Preclinical data showcased CTIM-76's broad therapeutic potential against CLDN6-positive tumors, addressing limitations of current therapies. CEO Martin Lehr anticipates filing an IND with the FDA in late Q1 2024 for CTIM-76. We'll be monitoring for future updates and a potential resistance breakout around $1.24.
Disclaimer: All content provided by BigTimePennys Report is for informational purposes only. The information provided should not be considered as a substitute for professional advice, analysis, or guidance. Any investment decisions made based on the information provided are solely at the user's own risk. BigTimePennys Report are not liable for any losses or damages incurred as a result of using this information. BigTimePenny is not operated by a licensed broker, a dealer, or a registered investment adviser. The Securities Litigation Reform Act of 1995 provides safe harbor protection for forward-looking statements made by companies or individuals. It should be noted that any forward-looking statements made by BigTimePennys Report, its authors, are not guarantees of future performance or results. These statements are subject to risks, uncertainties, and assumptions that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. The content provided by BigTimePennys Report does not constitute an endorsement, recommendation, or solicitation to buy, sell, or hold any securities or investment products. BigTimePennys Report, its authors, do not endorse or recommend any specific investment strategies, securities, or companies. It is crucial to conduct thorough research and seek advice from a qualified professional before making any investment decisions. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. The user assumes full responsibility for the use of the information provided by BigTimePennys Report. BigTimePennys Report, its authors, disclaim any liability for any direct, indirect, or consequential damages arising from the use or reliance on the information provided. Users should exercise their own judgment and discretion when interpreting and utilizing the information provided. Please note that the content provided by BigTimePennys Report is based on available information and sources believed to be reliable. However, market conditions and regulations may change over time, and there may be inaccuracies or errors in the information provided. It is recommended to verify the information with current and reliable sources before making any investment decisions. Investing in micro-cap companies is highly speculative and carries an extremely high degree of risk. BigTime Penny is not a fiduciary by virtue of any person's use of or access to this content.